you are here:

Ranbaxy Laboratories Ltd.

BSE: 500359 | NSE: RANBAXY | Series: NA | ISIN: INE015A01028 | SECTOR: Pharmaceuticals

BSE Live

Apr 01, 16:00
859.90 0.00 (0.00%)
Volume
No Data Available
308,222
  • Prev. Close

    859.90

  • Open Price

    814.90

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    0.00 (0)

Ranbaxy Laboratories is not traded on BSE in the last 30 days

NSE Live

Apr 01, 15:59
859.80 0.00 (0.00%)
Volume
No Data Available
5,415,702
  • Prev. Close

    859.80

  • Open Price

    814.70

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    859.80 (9924)

Ranbaxy Laboratories is not traded on NSE in the last 30 days

Annual Report

For Year :
2014 2012 2011 2010 2009 2008 2007 2006

Auditor's Report

1. Report on the Financial Statements We have audited the accompanying fnancial statements of Ranbaxy Laboratories Limited (the Company), which comprise the Balance Sheet as at 31 March 2014, and the Statement of Proft and Loss and the Cash Flow Statement for the ffteen months ended 31 March 2014 (current period), and a summary of signifcant accounting policies and other explanatory information. 2. Management''s Responsibility for the Financial Statements Management is responsible for the preparation of these fnancial statements that give a true and fair view of the fnancial position, fnancial performance and cash fows of the Company in accordance with the Accounting Standards referred to in sub-section (3C) of section 211 of the Companies Act, 1956 (the Act) read with the General Circular 15/2013 dated 13 September 2013 of the Ministry of Corporate Affairs in respect of section 133 of the Companies Act, 2013. This responsibility includes the design, implementation and maintenance of internal control relevant to the preparation and presentation of the fnancial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error. 3. Auditors'' Responsibility Our responsibility is to express an opinion on these fnancial statements based on our audit. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the fnancial statements are free from material misstatement. An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the fnancial statements. The procedures selected depend on the auditors'' judgement, including the assessment of the risks of material misstatement of the fnancial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company''s preparation and fair presentation of the fnancial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company''s internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by management, as well as evaluating the overall presentation of the fnancial statements. We believe that the audit evidence we have obtained is suffcient and appropriate to provide a basis for our audit opinion. 4. Opinion In our opinion and to the best of our information and according to the explanations given to us, the fnancial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India: (a) in the case of the Balance Sheet, of the state of affairs of the Company as at 31 March 2014; (b) in the case of the Statement of Proft and Loss, of the loss for the ffteen months ended on that date; and (c) in the case of the Cash Flow Statement, of the cash fows for the ffteen months ended on that date. 5. Emphasis of Matter Without qualifying our opinion, we draw attention to note 41 b) of the fnancial statements which explains in detail the prohibition imposed by the Food and Drug Administration of the United States of America on the Toansa manufacturing unit of the Company, and the communications received from/ actions taken by other regulators including the Department of Justice of the United States of America and regulators in European Union countries. Consequently, the Company has made provisions, to the extent of Rs. 2,862.78 million, on the basis of best information and estimates presently available with the Company. The basis and assumptions used by the management in calculating these provisions involve signifcant judgment and estimates (including those relating to inventories, sales return, trade commitments, realisability of tax assets, etc.). There are inherent uncertainties regarding the future actions of the regulators, the impact of which is not ascertainable at this stage and therefore, the actual amounts may eventually differ. 6. Report on Other Legal and Regulatory Requirements (i) As required by the Companies (Auditor''s Report) Order, 2003 (the Order), as amended, issued by the Central Government of India in terms of sub-section (4A) of section 227 of the Act, we give in the Annexure a statement on the matters specifed in paragraphs 4 and 5 of the Order. (ii) As required by provisions of section 227(3) of the Act, we report that: a. we have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit; b. in our opinion proper books of account as required by law have been kept by the Company so far as appears from our examination of those books; c. the Balance Sheet, the Statement of Proft and Loss and the Cash Flow Statement dealt with by this Report are in agreement with the books of account; d. in our opinion, the Balance Sheet, the Statement of Proft and Loss and the Cash Flow Statement comply with the accounting standards referred to in sub-section (3C) of section 211 of the Act read with the General Circular 15/2013 dated 13 September 2013 of the Ministry of Corporate Affairs in respect of section 133 of the Companies Act, 2013; e. on the basis of written representations received from the directors as on 31 March 2014 and taken on record by the Board of Directors, none of the directors are disqualifed as on 31 March 2014, from being appointed as a director in terms of clause (g) of sub-section (1) of section 274 of the Act. Annexure referred to in paragraph 6 of the Independent Auditors'' Report The Annexure referred to in our report to the members of Ranbaxy Laboratories Limited (the Company) for the ffteen months ended 31 March 2014. We report that: (i) (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of its fxed assets. (b) The Company has a regular programme of physical verifcation of its fxed assets through which all fxed assets are verifed, in a phased manner, over a period of three years. In our opinion, this periodicity of physical verifcation is reasonable having regard to the size of the Company and the nature of its assets. As informed to us, no material discrepancies were noticed on such verifcation as carried out under the above programme during the current period. (c) Fixed assets disposed off during the current period were not substantial, and therefore, do not affect the going concern assumption. (ii) (a) The inventories, except goods-in-transit, have been physically verifed by the management during the current period. In our opinion, the frequency of such verifcation is reasonable. (b) Subject to our comments in clause (xxi) below, in our opinion, the procedures of physical verifcation of inventories followed by the management during the current period are reasonable and adequate in relation to the size of the Company and the nature of its business. According to further information and explanations provided to us, the management has also carried out a physical verifcation of its inventory as at the period-end, wherein no instances of incorrect inventory management, as referred to in clause (xxi), below were noticed at the period end. (c) Subject to our comments in clause (xxi) below, the Company is maintaining proper records of inventories and the discrepancies observed on verifcation between the physical stocks and the book records were not material. The fndings referred to in clause (xxi) below have been adequately dealt with in the book records. (iii) The Company has neither granted nor taken any loans, secured or unsecured, to or from companies, frms or other parties covered in the register maintained under section 301 of the Companies Act, 1956 (''the Act''). (iv) In our opinion, and according to the information and explanations given to us, and having regard to the explanation that purchase of certain items of inventories and fxed assets are for the Company''s specialised requirements, and similarly, certain goods sold and services rendered are for the specialised requirements of the buyers and suitable alternative sources are not available to obtain comparable quotations, there is an adequate internal control system commensurate with the size of the Company and the nature of its business with regard to purchase of inventories and fxed assets, and for the sale of goods and services. In our opinion, and according to the information and explanations given to us, we have not observed any major weakness during the course of audit. (v) In our opinion, and according to the information and explanations given to us, there are no contracts and arrangements, the particulars of which need to be entered into the register maintained under section 301 of the Act. (vi) The Company has not accepted any deposits from the public. (vii) In our opinion, the Company has an internal audit system commensurate with the size and nature of its business. (viii) We have broadly reviewed the books of account maintained by the Company pursuant to the rules prescribed by the Central Government for maintenance of cost records under section 209(1)(d) of the Act, in respect of its products and are of the opinion that prima facie, the prescribed accounts and records have been made and maintained. However, we have not carried out a detailed examination of the records with a view to determine whether these are accurate or complete. (ix) (a) According to the information and explanations given to us, and on the basis of our examination of the records of the Company, amounts deducted / accrued in the books of account in respect of undisputed statutory dues including Provident Fund, Investor Education and Protection Fund, Employees'' State Insurance, Income Tax, Sales Tax, Wealth Tax, Service Tax, Customs Duty, Excise Duty and other material statutory dues have generally been regularly deposited during the current period by the Company with the appropriate authorities, though there has been a slight delay in a few cases. According to the information and explanations given to us and on the basis of our examination of the records of the Company, no undisputed amounts payable in respect of Provident Fund, Investor Education and Protection Fund, Employees'' State Insurance, Income Tax, Sales Tax, Wealth Tax, Service Tax, Customs Duty, Excise Duty and other material statutory dues were in arrears as at 31 March 2014 for a period of more than six months from the date those became payable. (b) According to the information and explanations given to us, there are no dues of Income Tax, Wealth Tax and Customs Duty which have not been deposited with the appropriate authorities on account of any dispute. According to the information and explanations given to us, the following dues of Excise Duty, Entry Tax, Value Added Tax, Service Tax and Sales Tax have not been deposited by the Company on account of disputes: Nature of Amount Name of the Statute the dues (Rs. in millions) Central Excise Act,1944 Excise Duty 20.51 Central Excise Act,1944 Service Tax 4.48 Central Excise Act,1944 Excise Duty 1.95 Central Excise Act,1944 Excise Duty 3.77 Central Excise Act,1944 Excise Duty 0.34 Name of the Statute Period to which the Forum where dispute is amount relates to pending Central Excise Act,1944 2001-02, May 2003 to Customs, Excise and Service December 2007, 2004 Tax Appellate Tribunal and 2005, 2007, 2008 (CESTAT), Delhi and 2006 to 2010 Central Excise Act,1944 2006 to 2011 CESTAT, Delhi Central Excise Act,1944 2004 to 2007 CESTAT, Mumbai Central Excise Act,1944 2005 to 2009 Commissioner (Appeals), Chandigarh Central Excise Act,1944 2011 to 2012 Commissioner (Appeals), Chandigarh (x) The accumulated losses of the Company at the end of the current period are not less than ffty percent of its net worth (without adjusting accumulated losses). As explained to us, these are primarily due to provision created (net of reversal) for settlement with the Department of Justice (DOJ) of the United States of America for resolution of civil and criminal allegations by the DOJ (refer to note 8 of the fnancial statements) in earlier years. The Company has incurred cash losses in the current period, though it had not incurred cash losses in the immediately preceding fnancial year. (xi) In our opinion, and according to the information and explanations given to us, the Company has not defaulted in repayment of dues to its bankers, debentureholders and fnancial institutions. (xii) The Company has not granted any loans and advances on the basis of security by way of pledge of shares, debentures and other securities. (xiii) In our opinion and according to the information and explanations given to us, the Company is not a chit fund or a nidhi/ mutual beneft fund / society. (xiv) According to the information and explanations given to us, the Company is not dealing or trading in shares, securities, debentures and other investments. (xv) In our opinion and according to the information and explanations given to us, the terms and conditions on which the Company has issued letters of comfort and given guarantees for loans taken from banks by subsidiaries and an associate company respectively, are not prejudicial to the interests of the Company. (xvi) In our opinion and according to the information and explanations given to us, except for term loans lying unutilised as at 31 March 2014, the term loans taken by the Company have been applied for the purpose for which these were raised. (xvii) According to the information and explanations given to us and on an overall examination of the Balance Sheet of the Company as at 31 March 2014, we are of the opinion that short term funds ofRs. 35,175.73 million have been used for long-term purposes primarily on account of accumulated losses including those related to settlement with the DOJ of the United States of America for resolution of civil and criminal allegations by the DOJ (refer to note 8 of the fnancial statements). (xvii) The Company has not made any preferential allotment of shares during the current period to companies/parties covered in the register maintained under section 301 of the Act. (xviii) According to the information and explanations given to us, the Company has not issued debentures during the current period. (xix) The Company has not raised any money by public issues during the current period. (xxi) As explained in note 41 c) of the fnancial statements; during the current period, the Company has written-down carrying amount of inventory by Rs. 424 million, consequent to the fndings of an exercise carried out by the management in response to certain internal information received by it. The fndings primarily concluded intentional incorrect inventory management of certain intermediate products by certain manufacturing unit level staff resulting in yield mismanagement and consequent incorrect higher quantity of inventories. Being a pharmaceutical quality related technical matter, we have relied on the management''s assessment of the said adjustment. As informed to us, appropriate actions have been taken by the Company including strengthening of internal controls. Subject to these comments, according to the information and explanations given to us, no fraud on or by the Company has been noticed or reported during the course of our audit. For B S R & Co. LLP Chartered Accountants Registration No. 101248W Akhil Bansal Place : Gurgaon, India Partner Dated : 9 May 2014 Membership No.: 090906